Sanofi is in talks to buy Flexion Therapeutics, a Boston-area biotech with its lead product now awaiting FDA approval, for more than $1 billion in cash, according to a source close to the deal.
Flexion’s board has accepted Sanofi’s non-binding offer, with a price in the “mid-30s” per share, the source said, with a final price pending due diligence. Flexion stock closed Wednesday at $19.68.
Flexion’s knee injection for osteoarthritis, Zilretta, would fit right in with Sanofi’s biosurgery division, which markets its own osteoarthritis injectable, Synvisc. And some of Flexion’s staffers know that product well; marketing VP Mark Fraga and medical affairs VP Scott Kelley, M.D., jumped to Flexion last year from jobs handling Synvisc at Sanofi.
Accepted for review in December, Zilretta could win FDA approval in October.
Sanofi refused to comment on the potential deal. Flexion spokesman Scott Young said he “can’t comment on market speculation or rumors.”
“We’re pursuing an independent strategy to commercialize our lead product Zilretta,” Young said Thursday.
The talks are ongoing and the transaction may not come to fruition, the source said. But if due diligence goes well and a binding offer is accepted, the cash deal could close quickly, giving Sanofi’s Genzyme unit several months to gear up for the Zilretta launch.
Zilretta is a sustained-release corticosteroid first up for approval for use in the knee. Analysts have suggested it could bring in $500 million to $600 million in peak sales, and perhaps hit blockbuster status if it wins indications for use in other joints.
Synvisc works differently; it’s a hyaluronon-based injection designed to supplement the natural fluid in the knee. It brought in €408 million for Sanofi in 2016, with €313 million of that in the U.S.
Sanofi has been deal-shopping as its diabetes franchise slows, eyeing companies with price tags in the bolt-on range—as Flexion would be—as well as bigger targets. It’s had some trouble bringing those bigger deals across the finish line, however; it lost out to Pfizer on the cancer biotech Medivation last summer and to Johnson & Johnson in its attempt to snap up Swiss-based Actelion late last year.
By Tracy Staton
Source: Fierce Pharma
Giovanni Caforio, the former CEO of Bristol Myers Squibb, is set to become the next board chairman of Novartis, which on Tuesday proposed the pharmaceutical industry veteran as its pick to replace Joerg Reinhardt in the role next year. Reinhardt has served as Novartis’ chair since 2013 and plans to retire when his 12-year term ends in 2025.
GE HealthCare has raised the curtain on two ultrasound systems equipped with artificial intelligence programs designed to assist in diagnosing conditions in women’s health, including obstetric exams. The Voluson Signature 20 and 18 imaging systems include AI tools capable of automatically identifying and annotating measurements of fetal anatomy.
Scientists from the University of Edinburgh’s School of Chemistry have revealed a new sustainable method of manufacturing complex molecules that could reduce waste produced during drug production. The method published in Nature Chemistry could help to prevent severe side effects caused by drugs that can exist as enantiomers.
